Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Defence Therapeutics ( (TSE:DTC) ) has issued an update.
Defence Therapeutics Inc. has strengthened its patent portfolio with key patent issuances and allowances across several jurisdictions, particularly enhancing its Accum® dimer and multimer technology. These developments are expected to provide Defence with market exclusivity until 2043 and validate its innovative approach, facilitating future licensing agreements and strategic partnerships to advance its anti-cancer therapeutics and vaccine technologies.
More about Defence Therapeutics
Defence Therapeutics Inc. is a Canadian biopharmaceutical company specializing in the development of radiopharmaceuticals, ADC products, and immune-oncology vaccines using proprietary platform and drug delivery technologies.
YTD Price Performance: 0.0%
Average Trading Volume: 888
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $21.26M
See more insights into DTC stock on TipRanks’ Stock Analysis page.
